Biofeedback Intervention for Paroxysmal Atrial Fibrillation

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorLiverpool John Moores University

About this trial

This project aims to bridge the gap between technology and healthcare by developing a biofeedback intervention that enables daily monitoring of atrial fibrillation episodes and physical activity levels. The main question it aims to answer is:

Is a co-designed, usability-tested, bio-feedback intervention aimed at nudging patients with paroxysmal atrial fibrillation to increase physical activity feasible for a larger randomised control trial?

The trial is split into two separate phases, each adopting different study designs, data collection, and data analysis methods.

Phase 1 Co-design and usability testing:

In this phase, we aim to test if smartwatches can be used to monitor AF and physical activity so that personalised atrial fibrillation-specific summaries can be created and sent to participants as text message nudges. The aim is to encourage participants to be more physically active.

Participants will wear a smartwatch for 3 weeks, during which they will receive text messages giving them feedback on their atrial fibrillation and physical activity. After the 3 weeks, all participants will take part in a workshop to provide feedback on what they thought and what could be improved. Improvements will be implemented by the researchers, and the process will repeat for a total of two iterations. On the first iteration only, participants will also be asked to wear a Holter monitor OR chest strap and an additional smartwatch for the first 24 hours, alongside an accelerometer watch for the first 7 days.

Phase 2 Feasibility study with embedded process evaluation:

This phase aims to assess whether it is feasible and acceptable to run a larger trial across the UK (i.e. can the intervention be delivered properly and do patients think it is useful).

Participants will be randomly allocated to either their normal standard of care, or to receive a smartwatch with the biofeedback messaging service in addition to their normal standard of care. The study will take 6 and a half months in total. Both groups will complete online questionnaires periodically over this period. Both groups will also need to wear a smartwatch and accelerometer watch for 7 days before and after testing.

Eligibility criteria

Qualifiers

Participant is willing and able to give informed consent for participation in the study.

Aged 18 or over.

Diagnosed with paroxysmal AF

Deemed medically stable and well managed.

Disqualifiers

Any concurrent cardiac arrhythmia

Blood pressure >180/100

Unstable angina

Myocardial infarction within the previous 3 months

Trial design

Treatments tested in this trial

  • Biofeedback intervention

Treatment groups

40 Participants
are divided into 2 treatment groups

Sponsors and collaborators

Liverpool John Moores University

Lead sponsor

Liverpool Heart and Chest Hospital NHS Foundation Trust

Collaborator